Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia

L.V. Prasad Eye Institute

Overview

Intravitreal pegaptanib for treatment of choroidal neovascularisation secondary to pathologic myopia

This is a Prospective Interventional, non-comparative study in 20 consecutive patients who will be selected from the outpatient services. After taking an informed consent, the patients will be given intravitreal Pegaptanib 0.3 mg every 6 weeks for 3 procedure of injection. Thereafter, patients will continue to be examined every 6 weeks (± 2 weeks) and of may receive additional injections as needed based on the presence of one or more re-treatment criteria (please see below). Final assessment will be done at 54 weeks and all the baseline investigations will be performed.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Myopic Choroidal Neovascular Membrane

Interventions

Intravitreal PegaptanibDRUG

Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Should be willing to participate in the trial. 2. Age less than 55 years. 3. Best corrected visual acuity (BCVA) score of at least 5 letters (20/200), as assessed by ETDRS chart. 4. Myopia of ≥ 6 Diopters. 5. Fluorescein angiographic documentation of CNV. Exclusion Criteria: 1. Ocular causes, or other ocular disorders leading to vision loss. 2. Maculopathy not related to pathologic myopia. 3. Pregnancy, lactation. 4. Not willing to provide an informed consent. 5. History of previous macular laser including PDT. 6. Other forms of therapy including intravitreal injections. 7. History of intraocular surgery in the past 3 months. 8. Anticipated cataract surgery in the next 6 months. 9. Any active infection or inflammation in the eye. 10. Cases where good quality imaging is not possible, either due to hazy media or extremely high myopia. 11. Patients with uncontrolled glaucoma, with IOP \> 21mm Hg on 2 or more medications. 12. Patients with subfoveal scar or significant subretinal haemorrhage occupying more than 50% of lesion size. 13. Eyes with previous retinal detachment.

Locations (1)

LV Prasad Eye Institute

Hyderabad, Andhra Pradesh, India

Outcomes

Primary Outcomes

Visual Acuity

Mean change in visual acuity from baseline to 54 weeks as measured by ETDRS chart

Time frame: 12 months

Secondary Outcomes

Mean change in macular thickness on OCT from baseline to 54 weeks

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.